Beam Therapeutics (NASDAQ: BEAM) was up 14% midday Monday on the back of Intellia Therapeutics‘ (NASDAQ: NTLA) phase 1 data for its therapy to treat a genetic liver disorder.
All of the companies associated with the gene-editing technique are having a good day thanks to the data. Although the treatment for the fatal disease — transthyretin (ATTR) amyloidosis — is great news, the implications go far beyond any one disease.